Weiss Ratings Reaffirms Sell (D-) Rating for Coya Therapeutics (NASDAQ:COYA)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Coya Therapeutics (NASDAQ:COYA), signaling ongoing concerns about the company's stock performance.
• Coya Therapeutics' shares dropped 9.7% to $6.30, with the company reporting a significant earnings miss and declining revenues in its last quarterly earnings.
• Despite the negative rating from Weiss, five research analysts have issued "buy" ratings on Coya Therapeutics, with an average target price of $16.20.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a report released on Friday,Weiss Ratings reports.

COYA has been the subject of a number of other reports. BTIG Research restated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, September 30th. Lake Street Capital began coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, September 29th. Chardan Capital reiterated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday, September 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, August 25th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $16.20.

Coya Therapeutics Stock Down 9.7%

Shares of NASDAQ:COYA traded down $0.68 during midday trading on Friday, reaching $6.30. The company's stock had a trading volume of 1,122,095 shares, compared to its average volume of 198,502. The firm has a market capitalization of $105.40 million, a PE ratio of -5.08 and a beta of 0.19. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The stock has a fifty day moving average of $6.20 and a 200 day moving average of $6.00.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.78 million. Sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. acquired a new position in shares of Coya Therapeutics during the 1st quarter worth approximately $65,000. Jane Street Group LLC boosted its stake in Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after buying an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the second quarter worth $119,000. CM Management LLC boosted its stake in Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after buying an additional 40,000 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in Coya Therapeutics during the first quarter worth $1,083,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.